Maryland Commission for Women - Maryland Collaborative to Advance Implementation of Coverage of Over-the-Counter Birth Control
HB939 requires the Maryland Commission for Women to create the Maryland Collaborative to Advance Implementation of Coverage of Over-the-Counter Birth Control. The collaborative is a temporary, multi-stakeholder body charged with studying how Maryland can better implement and expand access to over-the-counter contraception, including coverage at pharmacies, point-of-sale options at retail counters and virtual platforms, and even vending machines. It is also directed to examine public education and outreach strategies, especially for people who currently lack coverage or cannot effectively use existing coverage options.
The bill specifies a broad membership that includes state agencies, reproductive health advocates, insurers, pharmacy and retail representatives, managed care organizations, pharmacy benefits managers, and higher education/student health insurance representatives. The collaborative must review federal guidance and recent policy materials, consult with relevant stakeholders, and produce an interim report by January 1, 2026, and a final report by December 1, 2027. The act takes effect July 1, 2025, and sunsets on June 30, 2028.
HB939 does not directly change insurance coverage mandates or pharmacy practice rules in the text of the act; instead, it creates a study and recommendation process intended to inform future implementation of Maryland’s existing over-the-counter birth control coverage framework. Its practical impact is to place the Maryland Commission for Women in a coordinating role and to formalize interagency and stakeholder collaboration around contraceptive access, with potential implications for state-regulated private plans, Medicaid, the State Employee and Retiree Health and Welfare Benefits Program, and the Maryland Health Benefit Exchange. The bill may influence future administrative or legislative action on how OTC contraception is covered and dispensed in Maryland.
The overall sentiment around the bill appears supportive and favorable. The bill passed both chambers with substantial majorities, indicating broad legislative backing for improving access to over-the-counter birth control and for Maryland’s continued leadership on reproductive health coverage. The bill’s findings and preamble frame the measure as a reproductive freedom and access initiative, and the absence of recorded committee transcript opposition suggests limited publicized controversy in the available materials.
The main points of potential contention are not about whether access to birth control should be improved, but about how coverage should be implemented in practice. Likely areas of debate include the feasibility of point-of-sale coverage, the role of pharmacies and retailers, the administrative burden on insurers, pharmacy benefit managers, and managed care organizations, and whether coverage should extend through retail counters, online platforms, or vending machines. There may also be differing views on the scope of state involvement in reproductive health policy and on the inclusion of a broad set of stakeholders, including reproductive justice organizations and industry representatives, in the collaborative.